
    
      The study is a randomized, double-blind phase 1 trial including 2 sequential parts: single
      ascending dose(SAD) part,multiple ascending dose(MAD) part. SAD and MAD are dose-escalated
      tolerant study designing. The aims of the study as below:

        1. Evaluating the safety and tolerance of ZG0418 in ALK+ NSCLC.

        2. Evaluating the fasting pharmacokinetic parameters of ZG0418 in ALK+ NSCLCJaktinib.

        3. Evaluating the postprandial pharmacokinetic parameters of ZG0418 in ALK+ NSCLC.

        4. Analysis the metabolites of ZG0418
    
  